Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (D.O. Ott Research Institute)
- Development stage
- Unknown
- Lead developer
- D.O. Ott Research Institute of Obstetrics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrauterine
01
Overview
This investigational cell therapy consists of autologous bone marrow-derived mesenchymal stem cells (MSCs) developed by the D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology. The therapy involves extracting MSCs from the patient's own bone marrow (iliac crest), cultivating them, and then transplanting them directly into the endometrial cavity. It is primarily indicated for treating infertility of uterine origin, specifically targeting conditions like Asherman syndrome, endometrial atrophy, and hypoplastic endometrium in patients with repeated IVF failures. The mechanism of action involves promoting endometrial repair and regeneration, increasing endometrial thickness, and improving receptivity for embryo implantation. In clinical trials, the procedure is typically performed on menstrual cycle days 5-6 and is combined with hormone replacement therapy (HRT).
- Other names
- autologous bone marrow-derived MSCsbone marrow-derived MSC
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (D.O. Ott Research Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (D.O. Ott Research Institute).